Johnson & Johnson JNJ reported stronger-than-expected second-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue...
/Bristol-Myers%20Squibb%20Co_%20logo%20on%20building-by%20tatu%20Campelo%20via%20iStock.jpg)
Pharma giant Bristol-Myers Squibb has notably outpaced the broader pharma industry over the past year and analysts remain moderately bullish on the stock’s prospects.
Johnson & Johnson JNJ infused positive optimism for the broader healthcare sector after posting solid third-quarter 2024 earnings on Oct. 15. The world's biggest healthcare products maker continued with...
/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Gilead Sciences has underperformed the broader market over the past year, yet Wall Street analysts remain moderately bullish about the stock’s prospects.
/Bristol-Myers%20Squibb%20Co_%20logo%20on%20phone%20by-%20Piotr%20Swat%20via%20Shutterstock.jpg)
Bristol-Myers Squibb has underperformed the market over the past year, and Wall Street analysts remain cautious about the stock prospects.
First Trust Advisors L.P. ("FTA") announces the declaration of distributions for 138 exchange-traded fund(s) (each a “Fund,” collectively, the “Funds”) advised by FTA.
First Trust Advisors L.P. ("FTA") announces the declaration of distributions for 129 exchange-traded fund(s) (each a “Fund,” collectively, the “Funds”) advised by FTA.
First Trust Advisors L.P. ("FTA") announces the declaration of distributions for 135 exchange-traded fund(s) (each a “Fund,” collectively, the “Funds”) advised by FTA.
First Trust Advisors L.P. ("FTA") announces the declaration of distributions for 120 exchange-traded fund(s) (each a “Fund,” collectively, the “Funds”) advised by FTA.
First Trust Advisors L.P. ("FTA") announces the declaration of distributions for 133 exchange-traded fund(s) (each a “Fund,” collectively, the “Funds”) advised by FTA.